GSTM1 and paroxysmal nocturnal hemoglobinuria: Since then, C5 inhibitors (C5i) ECU and subsequently ravulizumab (RAV), which was approved in 2018, have led to improved management and outcomes for patients with PNH, as measured by decreased transfusion dependence and Hb stabilization [7,8,9,10,11].